S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
New CBOE “special perk” helps traders target income every weekend (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
New CBOE “special perk” helps traders target income every weekend (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
New CBOE “special perk” helps traders target income every weekend (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
New CBOE “special perk” helps traders target income every weekend (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts

Bellicum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BLCM)

$0.22
+0.02 (+9.77%)
(As of 12/6/2023 ET)
Compare
Today's Range
$0.20
▼
$0.22
50-Day Range
$0.10
▼
$0.33
52-Week Range
$0.06
▼
$1.50
Volume
1,139 shs
Average Volume
834,820 shs
Market Capitalization
$2.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media

BLCM stock logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

BLCM Stock Price History

BLCM Stock News Headlines

December 2, 2023 | americanbankingnews.com
Bellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated at StockNews.com
October 27, 2023 | finance.yahoo.com
Futura Medical plc (FAMDF)
December 7, 2023 | Financial Alphas (Ad)
Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
July 13, 2023 | finance.yahoo.com
BLCM - Bellicum Pharmaceuticals, Inc.
June 3, 2023 | fool.com
Bellicum Pharmaceuticals (NASDAQ: BLCM)
May 8, 2023 | investorplace.com
Why Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?
April 18, 2023 | msn.com
Why Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket
April 18, 2023 | benzinga.com
Short Volatility Alert: Bellicum Pharma
December 7, 2023 | Edge On The Street (Ad)
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
March 15, 2023 | msn.com
BLCM Plummets on Stopping Trials of BPX-601 and BPX-603
March 15, 2023 | msn.com
Why Bellicum Pharmaceuticals (BLCM) Stock Is Down 48%
March 14, 2023 | finance.yahoo.com
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
February 24, 2023 | finance.yahoo.com
Why Bellicum Pharmaceuticals Stock Is Plunging Today
February 16, 2023 | finance.yahoo.com
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
January 31, 2023 | finance.yahoo.com
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2023 | finance.yahoo.com
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
November 13, 2022 | finanznachrichten.de
Bellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 10, 2022 | finance.yahoo.com
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
October 4, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
September 15, 2022 | seekingalpha.com
BLCM Bellicum Pharmaceuticals, Inc.
September 1, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
August 18, 2022 | finance.yahoo.com
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
August 11, 2022 | finance.yahoo.com
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
May 13, 2022 | seekingalpha.com
Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42
May 13, 2022 | finance.yahoo.com
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
March 24, 2022 | finance.yahoo.com
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
CUSIP
N/A
CIK
1358403
Web
www.bellicum.com
Phone
(281) 454-3424
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,970,000.00
Net Margins
N/A
Pretax Margin
-1,492.40%
Return on Equity
-753.03%
Return on Assets
-157.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.04
Quick Ratio
3.04

Sales & Book Value

Annual Sales
$1.50 million
Price / Sales
1.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
0.98

Miscellaneous

Outstanding Shares
9,500,000
Free Float
8,518,000
Market Cap
$2.14 million
Optionable
Not Optionable
Beta
1.59
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Charles S. Grass (Age 63)
    Principal Accounting Officer
  • Mr. Joseph Senesac (Age 53)
    Senior Vice President of Technical Operations & Quality
  • Dr. Alan K. Smith Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $536.43k

Key Competitors

View All Competitors














BLCM Stock Analysis - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
View BLCM analyst ratings or view top-rated stocks.

How have BLCM shares performed in 2023?

Bellicum Pharmaceuticals' stock was trading at $0.72 at the beginning of the year. Since then, BLCM stock has decreased by 68.8% and is now trading at $0.2248.
View the best growth stocks for 2023 here.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its quarterly earnings data on Tuesday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $1 million for the quarter.

When did Bellicum Pharmaceuticals' stock split?

Shares of Bellicum Pharmaceuticals reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BLCM) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -